Category Archives: Nanomedicine

PARIS, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN : FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced the trading resumption of its ordinary shares on Euronext in Paris (Euronext Paris) as from 4:00 pm CET.

Trading in the ordinary shares of Nanobiotix was halted at the request of the Company on December 11, 2020 from 9:00 am CET in connection with its previously announced global offering, in order to allow for the confirmation of allocations to investors and for the commencement of trading of the Companys American Depositary Shares on the Nasdaq Global Select Market.

About NANOBIOTIX

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). Its headquarters are in Paris, France. Nanobiotix has a subsidiary, Curadigm, located in France and the United States, as well as a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.

Important Notice

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix registered with the AMF under number R.20-010 on May 12, 2020 as completed by an amendment to such universal registration document filed with the AMF under number D.0339-A01 on November 20, 2020 (copies of which are available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of ordinary shares or ADSs of Nanobiotix in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

A French listing prospectus comprising (i) the 2019 universal registration document filed with the AMF under number R.20-010 on May 12, 2020, as completed by a first amendment to such universal registration document filed with the AMF under number D.0339-A01 on November 20, 2020 and a second amendment to such universal registration document, which will be filed with the AMF on December 11, 2020, and (ii) a Securities Note (Note dopration), including a summary of the prospectus, will be submitted to the approval by the AMF and will be published on the AMFs website at http://www.amf-france.org. Following the filing of the second amendment to the universal registration document with the AMF, copies of Companys 2019 universal registration document, as amended, will be available free of charge at the Companys head office located at 60 rue de Wattignies, 75012 Paris.

European Economic Area

In relation to each Member State of the European Economic Area (each, a Member State) no offer to the public of ordinary shares and ADSs may be made in that Member State other than:

- to any legal entity which is a qualified investor as defined in the Prospectus Regulation;- to fewer than 150 natural or legal persons (other than a qualified investor as defined in the Prospectus Regulation); or- in any other circumstances falling within Article 1(4) of the Prospectus Regulation,

provided that no such offer of ordinary shares and ADSs shall require us or any Underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the Underwriters and the Company that it is a qualified investor as defined in the Prospectus Regulation.

For the purposes of this provision, the expression an offer to the public in relation to any ordinary shares and ADSs in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any ordinary shares and ADSs to be offered so as to enable an investor to decide to purchase any ordinary shares and ADSs, and the expression Prospectus Regulation means Regulation (EU) 2017/1129 (as amended).

France

The ADSs and the ordinary shares have not been and will not be offered or sold to the public in the Republic of France, and no offering of this prospectus or any marketing materials relating to the ADSs and the ordinary shares may be made available or distributed in any way that would constitute, directly or indirectly, an offer to the public in the Republic of France (except for public offerings defined in Article L.411-2 1 of the French Code montaire et financier).

The ordinary shares in the form of ADSs may only be offered or sold in France pursuant to article L. 411-2 1 of the French Code montaire et financier to qualified investors (as such term is defined in Article 2(e) of Regulation (EU) n 2017/1129 dated 14 June 2017, as amended) acting for their own account, and in accordance with articles L. 411-1, L. 411-2 and D. 411-2 to D.411-4, D.744-1 and D. 754-1 and D. 764-1 of the French Code montaire et financier.

This announcement is not an advertisement and not a prospectus within the meaning of the Prospectus Regulation.

See the article here:
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris - Business Wire

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN : FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the filing of an amended registration on form F-1 in connection with its intention to issue and sell, subject to market and other conditions, 6,500,000 ordinary shares of the Company in an initial public offering of American Depositary Shares (ADSs), each representing the right to receive one ordinary share, in the United States (the U.S. Offering) and a concurrent offering of ordinary shares in certain jurisdictions outside the United States to certain investors (the European Offering and together with the U.S. Offering, the Global Offering). The offering price per ADS is expected to be between $13.50 and $14.50, or between 11.15 and 11.97 per ordinary share (assuming an exchange rate of 1.00 = $1.2109, the exchange rate published by the European Central Bank on December 9, 2020).

Assuming an offering price of $14.00 per ADS in the U.S. Offering and 11.56 per ordinary share in the European Offering, which are the midpoints of the respective price ranges, the Company expects to receive net proceeds of approximately $79.6 million (65.8 million) from the Global Offering. The Company intends to grant the underwriters a 30-day option to purchase, at the same price, additional ADSs and/or ordinary shares in an aggregate amount of up to 15% of the total number of ADSs and ordinary shares proposed to be sold in the Global Offering. If such option is exercised in full, the expected net proceeds to the Company will increase to approximately $92.3 million (76.2 million).

All securities to be sold in the Global Offering will be offered by the Company. The ADSs have been approved for listing on the Nasdaq Global Select Market under the ticker symbol NBTX. The Companys ordinary shares are listed on the regulated market of Euronext Paris under the ticker symbol NANO.

The Company plans to use the net proceeds of the Global Offering to advance the overall development of NBTXR3, prioritizing the treatment of locally advanced head and neck cancers, including approximately $58.1 million to advance its clinical trial of NBTXR3 in the United States and Europe for the treatment of locally advanced head and neck cancers through an interim analysis of efficacy data, and approximately $20.6 million to advance the development of its other clinical and pre-clinical programs. The Company expects to use the remainder of the net proceeds, if any, from the Global Offering for working capital funding and other general corporate purposes.

The Company expects that the net proceeds from the Global Offering, together with its cash and cash equivalents of 42.4 million as of September 30, 2020, will be sufficient to fund its operating expenses and capital expenditure requirements through the end of 2022.

Jefferies LLC is acting as global coordinator and joint book-running manager for the Global Offering, and Evercore Group, L.L.C. and UBS Securities LLC are acting as joint book-running managers for the U.S. Offering. Jefferies International Limited and Gilbert Dupont are acting as managers for the European Offering.

The final offering price per ADS in U.S. dollars and the corresponding offering price per ordinary share in euros, as well as the final number of ADSs and ordinary shares to be sold in the Global Offering, will be determined by the Companys executive board following a bookbuilding process commencing immediately. The offering price per ADS and per ordinary share will be at least equal to the volume weighted average price of the Companys ordinary shares on the regulated market of Euronext in Paris over the last three trading days preceding the start of the offering (i.e., December 7, 8 and 9, 2020), subject to a maximum discount of 10%.

On an indicative basis, the completion of the Global Offering would result in a dilution of approximately 25% of the Company's outstanding share capital on a non-diluted basis (excluding the exercise by the underwriters of the option to purchase additional ordinary shares) and approximately 28% of the Companys outstanding share capital on a non-diluted basis (in the event that the underwriters exercise in full their option to purchase additional ordinary shares (including in the form of ADSs)).

The ADSs and/or ordinary shares will be issued through a capital increase without shareholders preferential subscription rights by way of a public offering excluding offerings referred to in Article L. 411-2 1 of the French Monetary and Financial Code (Code montaire et financier) and under the provisions of Article L.225-136 of the French Commercial Code (Code de commerce) and pursuant to the 2nd and 7th resolutions of the Company's extraordinary general shareholders' meeting held on November 30, 2020. The European Offering will be open only to qualified investors as such term is defined in article 2(e) of the regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017.

The Company plans to announce the result of the Global Offering as soon as practicable after pricing thereof in a subsequent press release.

The existing liquidity contract between the Company and Gilbert Dupont is suspended until the end of the stabilization period.

The securities referred to in this press release will be offered only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the Global Offering may be obtained from Jefferies LLC, 520 Madison Avenue New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at Prospectus_Department@Jefferies.com; or from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at 888-474-0200, or by email at ecm.prospectus@evercore.com; or from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019, or by telephone at 888-827-7275, or by email at ol-prospectusrequest@ubs.com.

A registration statement on Form F-1 relating to the securities referred to herein has been filed with the U.S. Securities and Exchange Commission (SEC) but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The registration statement can be accessed by the public on the website of the SEC.

About NANOBIOTIX

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). Its headquarters are in Paris, France. Nanobiotix has a subsidiary, Curadigm, located in France and the United States, as well as a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.

Disclaimer

This press release contains certain forward-looking statements concerning the Global Offering as well as Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix registered with the AMF under number R.20-010 on May 12, 2020 and in its amendment filed with the AMF under number D.0339-A01 on November 20, 2020 (copies of which are available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of ordinary shares or ADSs of Nanobiotix in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

A French listing prospectus comprising (i) the 2019 universal registration document filed with the AMF under number R.20-010 on May 12, 2020, as completed by a first amendment to such universal registration document filed with the AMF under number D.0339-A01 on November 20, 2020 and a second amendment to such universal registration document, which will be filed with the AMF on December [11], 2020, and (ii) a Securities Note (Note dopration), including a summary of the prospectus, will be submitted to the approval by the AMF and will be published on the AMFs website at http://www.amf-france.org. Following the filing of the second amendment to the universal registration document with the AMF, copies of Companys 2019 universal registration document, as amended, will be available free of charge at the Companys head office located at 60 rue de Wattignies, 75012 Paris.

European Economic Area

In relation to each Member State of the European Economic Area (each, a "Member State") no offer to the public of ordinary shares and ADSs may be made in that Member State other than:

For the purposes of this provision, the expression an "offer to the public" in relation to any ordinary shares and ADSs in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any ordinary shares and ADSs to be offered so as to enable an investor to decide to purchase any ordinary shares and ADSs, and the expression "Prospectus Regulation" means Regulation (EU) 2017/1129 (as amended).

France

The ADSs and the ordinary shares have not been and will not be offered or sold to the public in the Republic of France, and no offering of this prospectus or any marketing materials relating to the ADSs and the ordinary shares may be made available or distributed in any way that would constitute, directly or indirectly, an offer to the public in the Republic of France (except for public offerings defined in Article L.411-2 1 of the French Code montaire et financier).

The ordinary shares in the form of ADSs may only be offered or sold in France pursuant to article L. 411-2 1 of the French Code montaire et financier to qualified investors (as such term is defined in Article 2(e) of Regulation (EU) n 2017/1129 dated 14 June 2017, as amended) acting for their own account, and in accordance with articles L. 411-1, L. 411-2 and D. 411-2 to D.411-4, D.744-1 and D. 754-1 and D. 764-1 of the French Code montaire et financier.

This announcement is not an advertisement and not a prospectus within the meaning of the Prospectus Regulation.

MIFID II product governance / Retail investors, professional investors and ECPs only target market Solely for the purposes of each manufacturers product approval process, the target market assessment in respect of the new shares has led to the conclusion that: (i) the target market for the new shares is retail investors, eligible counterparties and professional clients, each as defined in MiFID II; and (ii) all channels for distribution of the new shares to retail investors, eligible counterparties and professional clients are appropriate. Any person subsequently offering, selling or recommending the new shares (a distributor) should take into consideration the manufacturers target market assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the new shares (by either adopting or refining the manufacturers target market assessment) and determining appropriate distribution channels. For the avoidance of doubt, even if the target market includes retail investors, the manufacturers have decided that the new shares will be offered, as part of the initial offering, only to eligible counterparties and professional clients.

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

Follow this link:
NANOBIOTIX Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Range - Business Wire

INTRODUCTION

For neurodegenerative diseases, gene and small-molecule drugs can be used for clearing pathological substances synergistically that cause neuronal degeneration (1). In Parkinsons disease (PD), -synuclein (-syn) aggregates are considered to be the main pathological substance (2, 3). Small interfering RNA (siRNA) shows potential in rare disease or disease with no good drug options but is gene related. For example, Onpattro (patisiran) has been applied as the clinical treatment of multiple sclerosis. siRNA targeting SNCA (siSNCA) can down-regulate -syn protein synthesis to inhibit the formation of -syn aggregates and could specifically down-regulate -syn expression without targeting - or -synuclein (4).The neuroprotective small-molecule drug curcumin has a reducing effect on the existing -syn aggregates (57). Therefore, the combination of siSNCA with curcumin can synergistically reduce the cytotoxicity of -syn aggregates on dopaminergic neurons for PD treatment. Even so, these drugs with poor bioavailability are difficult to accumulate in the action site of target neurons because of their poor absorption and rapid metabolism (8, 9). In addition, brain delivery problems are mainly manifested in the fact that it is difficult for delivery systems to pass through the blood-brain barrier (BBB) and could not accurately recognize the target cell (10). Synthetic gene and chemical drug (gene-chem) nanocomplexes including liposomes and polymer particles have been modified with cell-penetrating peptides or cell-targeting molecules for enhanced drug delivery in brain diseases or other disease therapy (11). However, synthetic nanocomplexes are easily recognized as foreigners, resulting in natural immune activation, cell apoptosis, and short blood circulation time, which is unsafe and with low efficiency (12). In addition, when being internalized, these synthetic carriers would undergo an endosomal-lysosomal pathway, which tends to cause drug degradation and exocytosis as well as leads to inflammasome activation (12). Furthermore, it is necessary to control the release of drugs in the lesion area to reduce nonspecific toxicity. Therefore, to efficiently deliver gene-chem drugs to the action site of target cells for safe PD therapy, it is necessary to develop a delivery system that could overcome these delivery bottlenecks including low BBB permeation, poor neuron targeting, inefficient endocytosis into cytoplasm, and uncontrolled drug release.

To realize the above aims, we designed a targeted exosome coating gene-chem nanocomplex as an engineering nanoscavenger for neuronal -syn aggregates and immune activation of PD. Exosome is a well-researched natural source carrier for siRNA and chemical drugs, with diameter of 30 to 100 nm (4, 13, 14). It has a membrane structure on whose surface the specific protein tetraspanin CD9 facilitates direct membrane fusion and helps the internal substances directly transport into the cytoplasm of the recipient cell, which avoids lysosomal trapping (15, 16). To further efficiently deliver drugs through the BBB and to the dopaminergic neurons, the first process of the engineering was constructing the shell, REXO, a targeted immature dendritic cell (imDC)derived exosome with modification of rabies virus glycoprotein (RVG) peptide with 29 amino acids, which could specifically bind to the acetylcholine receptor expressed by neuronal cells and the BBB (17). Because it was difficult for exosomes to load hydrophilic gene and hydrophobic small-molecule drugs simultaneously, the second process of the engineering was achieved as a product of a gene-chem coloaded core, which is a reactive oxygen species (ROS)responsive gene-chem drug nanocomplex loading these two drugs with different characteristics (8, 9). The third process of the engineering was REXO-C/ANP/S nanoscavenger preparation. REXO was coated on the nanocomplex to form a nanoscavenger. Therefore, the engineering delivery system could efficiently cross the BBB, target neurons, and release drugs in high ROS environment of diseased dopaminergic neurons. The enriched siSNCA and curcumin could have functions on -syn protein down-regulation and -syn aggregate inhibition synergistically.

Literatures indicated that neurodegenerative diseases are immune disorders (18, 19). For example, PD is an adaptive immune disorder because T cells are activated by pathological substances such as -syn peptides (20). In addition, studies have indicated that immune activation of PD was associated with T helper 17 (TH17) functions and that differentiated TH17 cells could induce the inflammatory response (21). In brain diseases, the factors secreted by TH17 cells would induce neuron apoptosis or death and enhance central nervous system inflammation (22). Moreover, regulatory T (Treg) cells could inhibit immune activation and maintain immune stability and tolerance due to interleukin-10 (IL-10) and transforming growth factor (TGF-). These cytokines could promote the survival of neurons (23), inhibit the differentiation of TH17 cells, activate macrophages and microglia, and exert anti-inflammatory effects (24). In addition, neuroprotection of Treg cells can be exerted by inhibiting the response of microglia to stimuli-nitrated -syn (25). It was well known that imDC had immunosuppressive effects and played an important role in autoimmune diseases (2628). Inspired by this, we further speculated that exosomes derived from imDC, which coat the hybrid system REXO-C/ANP/S, might have an effect on immunosuppression as imDC does (29). The study further confirmed that the hybrid system REXO-C/ANP/S was effective in inhibiting TH17 cell immune activation and promoting immunosuppression-related Treg cell functions in the nervous system.

The hybrid nanoparticle (NP) REXO-C/ANP/S was prepared from two parts (Fig. 1A): preparation of gene-chem core C/ANP/S and acquisition of REXO. The core C/ANP/S was obtained by a two-step process. First, we synthesized the polymers BA-poly(2-(dimethylamino)ethyl acrylate) (BAP) and BB-poly(2-(dimethylamino)ethyl acrylate) (BBP) (fig. S1A). BBP was used as a nonROS-responsive control (30). 1H nuclear magnetic resonance of BAP and BBP indicated their successful synthesis (fig. S1, B to D). The amphiphilic polymer BAP could self-assemble and encapsulate the hydrophobic drug curcumin to form curcumin/BAP NP (C/ANP). The loading rate of curcumin in NP was calculated by Multiskan Spectrum, and the value was 70%. Next, the final C/ANP/siSNCA (C/ANP/S) and C/BNP/siSNCA (C/BNP/S) nanocomplex was formed via electrostatic interaction (Fig. 1A). We used the gel retardation assay and found that the siSNCA was completely attached to C/ANP at N/P (nitrogen portion of polymer/phosphorus portion of siRNA) of 5 (fig. S2A). The nonROS-responsive C/BNP/S nanocomplex was prepared the same way, and it could also completely absorb siSNCA at an N/P ratio of 5 (fig. S2B). The morphology of C/ANP/S was a spherical shape of approximately 30 nm in diameter (fig. S2C). Furthermore, we simulated the cytoplasmic high ROS microenvironment of the diseased dopaminergic neuron in vitro and detected the ROS-responsive characteristics of both nanocomplexes (31). The nonROS-responsive C/BNP/S slowly released curcumin in the phosphate-buffered saline (PBS) and H2O2 environment, and the final release ratios were 16.5 and 17.5% at 390 min, respectively (fig. S2D). The C/ANP/S had a low release rate of 24.4% in the PBS environment, but curcumin was more easily released in the H2O2 environment at a rate of 96.7% at 390 min. Therefore, C/ANP/S had the ROS-responsive drug release ability based on the materials structure.

(A) Scheme of REXO-C/ANP/S preparation. (B) Zeta potential and diameters of NPs under different REXO:C/ANP/S ratios. (C) TEM images of NPs under different REXO:C/ANP/S ratios (I, low REXO:C/ANP/S ratio; II, intermediate; and III, high REXO:C/ANP/S ratio). Scale bars, 100 nm. (D) Comparison in zeta potential and diameters of REXO, C/ANP/S, and REXO/ANP/S. (E) Chitosan microsphere with REXO-C/ANP/S absorption. Cy5-siSNCA, blue; curcumin, green; and DiI-labeled exosome, red. (F) Western blot band of TSG101 and CD9 of EXO and REXO-C/ANP/S.

The second part was the preparation of RVG-modified exosome REXO (Fig. 1A). First, bone marrow cells were extracted from the bone marrow of mice and were induced to differentiate into imDCs in vitro (32). The cell culture medium on the seventh day of culture was then collected. The cells and cell debris were removed by centrifugation. Next, culture medium was concentrated by ultrafiltration and passed through a qEV size exclusion column (Izon Science). The specified number 7, 8, and 9 fractions containing exosomes were separated and collected. Transmission electron microscopy (TEM) was used to identify the imDC exosome as a vesicle structure, approximately 70 nm in hydrodynamic diameter and with zeta potential of 12.7 mV (Fig. 2E). Targeted exosome could be engineered by click chemistry (33), targeting peptide plasmid transfer, or membrane fusion (13, 34, 35). However, these methods are complicated and time-consuming. In this engineering method, stearoyl-RVG was used to embed in the interior of the exosome phospholipid bilayer (table S1) (36). The mass spectrum confirmed the successful synthesis of the stearoyl-RVG (fig. S3A). To make the stearoyl-RVG visual in NPs, we then labeled it with fluorescein isothiocyanate (FITC). Stearoyl-RVG-FITC was synthesized by the condensation of amino group in stearoyl-NH2 and carboxyl group in FITC-RVG (fig. S3B). After removing the unembedded stearoyl-RVG-FITC via ultrafiltration centrifugation, stearoyl-RVG-FITC was obtained. Stearoyl-RVG-FITC had a low solubility in PBS. Therefore, the improved fluorescence intensity of stearoyl-RVG-FITC in exosomes after the ultrasound method indicated its successful modification (fig. S3, C and D) (36). We further used the lipophilic dye DiD (red), which is a lipophilic tracer like DiR, to label exosomes (37). The colocalization coefficient of DiD exosomes and stearoyl-RVG-FITC was 0.95 (fig. S3E), indicating the successful modification of RVG on exosomes.

(A) NP internalization in Transwell cells in 12 hours. I: Scheme of Transwell instrument. II: Cy5-siRNA internalization of bEnd.3 cells (top) and the SH-SH5Y cells (bottom). III: Cy5 mean fluorescence intensity in NP-treated bEnd.3 cells in Transwell model. IV: Cy5 mean fluorescence intensity in NP-treated SH-SH5Y cells in the Transwell model. (B) Cy5 mean fluorescence intensity detected by flow cytometry in SH-SH5Y cells after NP incubation in 0 min, 30 min, 1 hour, 2 hours, 4 hours, and 6 hours. ns, not significant. (C) Assessment by CLSM of SH-SY5Y cells after NP incubation in 4 hours. Endosome was labeled with LysoTracker red. Cy5-siSNCA, green. (D) Assessment by CLSM of SH-SY5Y cells after NP incubation in 0 min, 5 min, 10 min, 30 min, and 1 hour. Cell membrane was labeled with CellMask deep red membrane stain, and exosome was labeled with DiI.*P < 0.05, **P < 0.01, and ***P < 0.001. DAPI, 4,6-diamidino-2-phenylindole.

The assembly of the inner core and the outer REXO was carried out by the ultrasonic method using a bath sonicator at a frequency of 40 kHz and a power of 100 W (Fig. 1A) (38). The assembly process was assumed to be as shown in Fig. 1B and verified by TEM, size, and zeta potential measurement (Fig. 1C). Among the REXO and C/ANP/S complexes, below the REXO-to-C/ANP/S mass ratio of 0.05, the REXO absorbed to the surface of part C/ANP/S (Fig. 1C, I). The size of NPs increased to 141.0 nm at a mass ratio of 0.01, and the zeta potential decreased to 7.05 mV. At the ratio of 0.05, there was an intermediate state. The size increased to 437.5 nm, and TEM showed that C/ANP/S was cross-linked by the REXO (Fig. 1C, II). The ratio was further increased and, lastly, negative charge dominated the NPs that tended to be stable. The final core-shell monodisperse assembly forms as shown in Fig. 1C (III) at a mass ratio of 0.1, indicating that the REXO was coated on the surface of the core nanocomplexes. The final NP REXO-C/ANP/S was negatively charged at 7.1 mV, and the hydrodynamic diameter was 118.1 nm (Fig. 1D). Next, to facilitate the visual observation of the assembly components, we prepared positively charged poly-chitosan microspheres, which allowed adsorption of negatively charged assemblies on the surface (Fig. 1E). The exosomes were labeled with the lipophilic dye DiI. The result clearly showed the colocalization of DiI exosome, Cy5-siRNA, and curcumin (Fig. 1E and fig. S3F). In addition, the REXO-C/ANP/S obtained after assembly had the protein TSG101 and CD9 of EXO (Fig. 1F), which further indicated the successful coating.

In vitro, we investigated the biocompatibility of core nanocomplex C/ANP/S and the core-shell REXO-C/ANP/S. C/ANP/S and REXO-C/ANP/S were cocultured with SH-SY5Y cells under different N/P ratio conditions. As examined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, the result showed that the cell viability of both groups was above 80%. The survival rate under the experimental condition N/P ratio of 5/1 was 93.9% (fig. S4A), which was suitable for in vivo application.

Next, the delivery process was simulated in vitro to explore drug delivery of REXO-C/ANP/S and C/ANP/S. First, we used the Transwell culture method to simulate the BBB (Fig. 2A, I). bEnd.3 cells were cultured in Transwell inserts (1 105 cells per polyester Transwell insert in six wells, pore diameter of 0.4 m, 4.67 cm2) for 7 days to a resulting monolayer with a transepithelial electrical resistance at least 200 ohmcm2. After adding NPs, Cy5 mean intensity fluorescence was detected by bioluminescence imaging using Kodak In-Vivo Imaging System FX Pro. The REXO coating significantly enhanced the uptake of siRNA drugs in C/ANP/S into bEnd.3 cells and then through the epithelial cells into lower SH-SY5Y cells (Fig. 2A, II to IV). As a comparison, the addition of free RVG peptide inhibited the promoting effect (Fig. 2A, II to IV). By comparing the uptake of siRNA in SH-SY5Y cells at different time points (Fig. 2B), it was found that the REXO coating significantly enhanced the uptake of the drugs in C/ANP/S. After 2 hours, the EXO and REXO coating groups EXO-C/ANP/S and REXO-C/ANP/S were significantly better than nude curcumin and siRNA (nude C + S) as well as the inner core C/ANP/S. This was because the C/ANP/S was endocytosed through the endosome-lysosome pathway due to quaternary amine compounds in the C/ANP/S, causing NP efflux and drug loss, so that the increased accumulation of drugs was not obvious with time (Fig. 2B) (39). The EXO-C/ANP/S and REXO-C/ANP/S avoided drug loss in the endosomal pathway after 2 hours, thereby enhancing drug accumulation. Second, the targeted RVG modification NP REXO-C/ANP/S more significantly increased the drug uptake than EXO-C/ANP/S. After the addition of the free RVG polypeptide, it inhibited the endocytosis of the drug due to its binding to the receptor on the cell surface, and the drug uptake was significantly reduced in the experimental results. Therefore, the results demonstrated that the exosome coating changed the endocytosis pathway, which has an important role in the increase of drug uptake.

Furthermore, to confirm the reason for the conjecture that the exosome coating C/ANP/S could avoid the drug loss of the endosome-lysosome pathway, we conducted an experiment to confirm whether the exogenous membrane fusion characteristics help. The results of the confocal laser scanning microscopy (CLSM) experiments showed a comparison of the endocytic mechanisms of the two systems (Fig. 2C). The core C/ANP/S was taken up through the endosome-lysosome pathway; thus, the drug aggregated in the endosomes (the overlap coefficient was 0.92 at 4 hours). However, the drug delivered by REXO-C/ANP/S was more dispersed in the cytoplasm, and therefore, there was less drug accumulation in the endosomes than C/ANP/S-treated cells (the overlap coefficient was 0.56 at 4 hours). Next, we labeled the exosomes with DiI and labeled the cell membrane with CellMask deep red membrane stain to detect the fusion of the two dyes in a short period. The fluorescence of DiI was enhanced with the extension of time, and it was apparently colocalized with the fluorescence of deep red membrane stain from 5 min to 1 hour (Fig. 2D and fig. S4B). These results demonstrated that the drug of REXO-C/ANP/S was enriched mostly through membrane fusion.

-Syn aggregates were the main pathological substance in PD neurons. Therefore, it was very important to clear the -syn aggregates and excess -syn for PD treatment (Fig. 3A). We constructed an SH-SY5Y cell line SNCAmCherrySH-SY5Y cell, which overexpressed SNCA-mCherry protein by plasmid transfection and cell selection. First, we examined the effects of exosomes and RVG-modified exosomes on the -syn expression and aggregates and found that there was almost no effect (fig. S4C). Next, nude drugs and different NPs were cocultured with SNCAmCherrySH-SY5Y cells for 2 days. The -syn aggregates in -synmCherryoverexpressing cell lines were observed by CLSM, in which mCherry was a red reporter for -syn (Fig. 3B). The results of the total -syn were also verified by Western blot [Fig. 3, C and D; 47 kDa (-syn was 18 kDa, and mCherry was 29 kDa)]. There was a significant decrease in -syn protein in the REXO-C/ANP/Streated cells, compared with the blank (PBS) and the nude drug curcumin and siSNCA (nude C + S) groups. Compared with C/ANP/S, NPs without ROS-responsive C/BNP/S, and nontargeted EXO-C/ANP/S, the REXO-C/ANP/S had a stronger down-regulation effect, indicating the superiority of membrane fusion, target, and controlled-release ability. In addition, REXO-C/ANP/S had a down-regulation advantage compared with the curcumin-free NP REXO-ANP/S and the siNonsense NP REXO-C/ANP/siNonsense. In addition, except the REXO-C/ANP/siNonsensetreated cells, the SNCA mRNA expression of NP-treated cells was lower than PBS-treated cells. The SNCA mRNA expression of REXO-C/ANP/Streated cells decreased 64% (Fig. 3E). Moreover, the enzyme-linked immunosorbent assay (ELISA) test showed that the -syn aggregates in the cells treated by the drug-loaded NP groups were significantly reduced (Fig. 3F). In particular, -syn aggregates in cells treated with gene-chem dual drug carrier REXO-C/ANP/S decreased most obviously. This was because the gene drug siSNCA avoided the development of excessive -syn aggregation by reducing the synthesis of -syn, and curcumin could directly inhibit -syn aggregates. This result was consistent with our prediction. The gene-chem dual drug carrier relieves the pressure on neurons caused by the -syn aggregate through the synergistic effect of two drugs. In addition, through dot blot experiments, similar results further showed that the gene-chem dual drug carrier reduced phosphorylated -syn, conformation-specific -syn aggregates, and oligomer A11 molecules, which were related molecularly to the formation of -syn aggregates (fig. S4D). Obviously, it was proven that synergistic REXO-C/ANP/S had a delivery advantage at the cell level, and these contributed to substantially effective -syn aggregate clearance. Furthermore, the changes in cellular ROS activity of nanomedicine-treated cells indicated their roles in anti-inflammation. The ROS level was evaluated in SNCAmCherrySH-SY5Y cells, and the intracellular ROS content was tested by CLSM. Treating the cells with curcumin-containing nanomedicine caused 2.7 times of ROS decrease (fig. S5) compared with treatment with PBS. However, the nanocarrier without curcumin REXO-ANP/S had little contribution to ROS decrease. Therefore, the results indicated that the curcumin loading in REXO-C/ANP/S had a strong role in inflammation regulation, but siSNCA alone had a weaker effect on ROS level than others in a short period of 72 hours.

(A) Scheme of REXO-C/ANP/S synergistic effect against -syn. (B) Effect of NPs on decrease in -syn aggregates after NPs were incubated with SNCAmCherrySH-SY5Y cells. Scale bars, 100 m. (C) Mouse -synmCherry (anti-syn antibody) protein levels relative to -actin by Western blot. Western blot band of cells incubated with different NPs. I, PBS; II, nude C + S; III, C/BNP/S; IV, C/ANP/S; V, EXO-C/ANP/S; VI, REXO-C/ANP/siNonsense; VII, REXO-ANP/S; and VIII, REXO-C/ANP/S. (D) Total -syn protein levels were quantified relative to -actin. (E) Total SNCA mRNA expression levels were quantified by quantitative reverse transcription polymerase chain reaction. (F) Total -syn aggregate expression levels were quantified by ELISA. In (B) to (D) and (F), NPs were incubated with cells for 72 hours. In (E), NPs were incubated with cells for 36 hours. **P < 0.01 and ***P < 0.001.

In vivo, the enrichment of NPs in tissues is a key visualization tool for drug delivery. We detected drug distribution by using Kodak In-Vivo Imaging System FX Pro. Since curcumin itself has fluorescence property (excitation, 425 nm; emission, 530 nm), drug enrichment in the brain can be visualized in that the RVG29 peptide enhanced its accumulation in the brain (fig. S6, A and B). The accumulation of drug in the brain could last at least 48 hours (fig. S6, C and D). The drug was colocalized with tyrosine hydroxylasepositive (TH+) neurons in the substantia nigra (SN) region in mice brain (fig. S6E), which was essential for treatment. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)induced mice model of PD were vein injected with REXO-C/ANP/S and other control NPs (1 mg/kg siSNCA) every other day. After 10 times of administration, behavioral measurements were recorded. PD mice showed bradykinesia in the open field, and they traversed less in the middle region (Fig. 4A, II). Quantitative data in the open field for 30 min showed that their total distance decreased, movement speed slowed, and the rest time required was getting longer [Fig. 4, B to D (II)]. Mice in the NP groups showed a trend of improvement in exercise, especially the REXO-C/ANP/S group [Fig. 4, B to D (III to VI)]. In the pole experiment, the time to the tip of the rod was significantly reduced after the REXO-C/ANP/S treatment (Fig. 4E). This advantage was also shown in the brain sections after mouse dissection. Neuronal repair in the PD mice injected with REXO-C/ANP/S was better than in other groups (Fig. 4, F and G). In addition, hematoxylin-eosin staining of NP-treated mice organ slides indicated their safety without burden on the mice liver or other organs (fig. S7).

(A) Open-field traveled trace of normal mice and different NP-treated PD mice. (B) Total distance traveled of normal mice and different NP-treated PD mice in open field instrument. (C) Total speed of normal mice and different NP-treated PD mice in open field instrument. (D) Total rest time of normal mice and different NP-treated PD mice in open field instrument. (E) Time it took the mice to climb to the top in pole test. (F) TH immunohistochemistry staining (anti-TH antibody) of the brain slides in treated mice SN region. (G) Numbers of TH+ neurons in the treated mice brain SN region. *P < 0.05, **P < 0.01, and ***P < 0.001.

Furthermore, to explore the reasons for the superiority of the drug carrier REXO-C/ANP/S in neuroprotection, we discuss it from two aspects. First, the pathological substance -syn in the neurons was a key substance that was needed to be cleared. By staining the SN region of treated mice, we concluded that the synergistic drug-loading C/ANP/S nanocomplex played a role in the clearance of -syn in TH+ neurons, but the scavenging effects of EXO-C/ANP/S and REXO-C/ANP/S were more pronounced, especially the targeted NP REXO-C/ANP/S (Fig. 5, A and C). This is due to the superior delivery advantages of targeted exosomes. In addition, we also explored improvements in the mouse immune microenvironment. The results indicated that T cell activation in mice with PD could be cleared by the action of the imDC exosomes coating themselves. After the mice were treated with NPs, we found that EXO-C/ANP/S, especially REXO-C/ANP/S, could significantly increase the expression of Fox p3 in CD4-positive (CD4+) T cells (Fig. 5, B and D). In addition, REXO-C/ANP/S could significantly increase TGF- and IL-10 in PD (Fig. 5, E and F). It has been proven that TGF- signaling exerts anti-inflammatory effects, mainly neuroprotective effects. In addition, IL-22 and IL-17 were related to autoimmune diseases and were highly expressed as immune cytokines. Activated TH17 cells secrete and produce IL-22 and IL-17 immune cytokines. As a result, REXO-C/ANP/S could significantly decrease the IL-22 and IL-17 factors in PD (Fig. 5, G and H). The results indicated that the exosomes from imDC could inhibit the immune activation of PD and that the target modification further enhanced their effect. In comparison, C/ANP/S had almost no effect on the immune regulation but instead activated the immune system. The results indicated that the exosomes from imDC could inhibit the immune activation of PD and that the target modification further enhanced their effect. Moreover, by staining the SN region of treated mice with phospho S129 -syn antibody or polymerized -syn MJFR-14-6-4-2 antibody from Abcam, we detected in pathological -syn that the scavenging effects of EXO-C/ANP/S and REXO-C/ANP/S were more pronounced on phosphorylated -syn and aggregated -syn, especially the targeted NP REXO-C/ANP/S (Fig. 5I and fig. S8).

(A) Immunofluorescence staining (anti-TH antibody and anti-syn antibody) of normal mice and different NP-treated PD mice. Scale bars, 50 m. (B) Immunofluorescence staining (anti-CD4 antibody and antiFox p3 antibody) of normal mice and different NP-treated PD mice. Scale bars, 50 m. The amplify images were the images in the white square, with a 5-m scale bar. (C) -Syn mean fluorescence intensity in (A). (D) Fox p3 mean fluorescence intensity in (B). (E) IL-10 concentration in serum of PD mice treated with NPs. (F) TGF- concentration in serum of PD mice treated with NPs. (G) IL-22 concentration in serum of PD mice treated with NPs. (H) IL-17 concentration in serum of PD mice treated with NPs. (I) Conformation-specific -syn aggregate immunohistochemistry staining (anti-conformationspecific MJFR -syn aggregate antibody) of the brain slides in treated mice SN region. *P < 0.05, **P < 0.01, and ***P < 0.001.

In summary, combining the natural delivery advantages of exosomes with synthesized gene-chem nanocomplex, we designed a REXO coating gene-chem nanocomplex with high enrichment of drugs in the action site of a target cell. The role of REXO-C/ANP/S across the BBB and membrane fusion functions in -syn aggregate clearance was confirmed at the cellular and animal levels. Efficient delivery of siRNA and chemical drugs by the target exosomes reduced the -syn aggregates in diseased dopaminergic neurons (Fig. 6).

In addition, because of the natural immunomodulatory properties of the imDC exosomes, we discussed its role in clearing immune activation, which may be caused by -syn peptides (20). TH17 cells and Treg cells are CD4+ T cell subsets. It has been reported that TH17 cells have a strong inflammatory effect and play an important role in chronic inflammation and autoimmune diseases. Treg cells have obvious immunosuppressive effects and play an important role in immune tolerance and immune homeostasis. This delivery system can provide a functionalized vector for immunotherapy of neurodegenerative diseases (Fig. 6). This functionalization and exosome derived from imDC cells are inherited by major histocompatibility complex class II (MHC II), CD80, CD86, and other costimulatory factors on the surface of imDC cells so that they also have immunosuppressive functions. Thus, regulation of TH17 and Treg cell balance, which is inhibition of TH17 differentiation and promotion of Treg production to induce immune tolerance, and reconstruction of immune homeostasis in vivo may be a therapeutic approach to neuronal protection in addition to the accumulation of misfolded proteins. Certain pathological substances, such as amyloid- protein of Alzheimers disease, are mostly the pathogenic cause of neurodegenerative diseases. Therefore, it can provide an efficient strategy for the treatment of neurodegenerative diseases.

Curcumin was acquired from Melonepharma (Dalian, China), and siSNCA (table S1), Cy5-siSNCA, and negative control siSNCA (siNonsense, antisense strand, 5-GACAAAUGUUGGAGGAGCATT-3) were synthesized by GenePharma Company (Suzhou, China). RVG peptide was purchased from GL Biochem Ltd. Co. (Shanghai, China). Other chemicals in synthesis were from J&K Scientific Ltd. MTT and MPTP were obtained from Sigma-Aldrich. SH-SY5Y cells and SNCAmCherrySH-SY5Y cell line culture were the same as in the previous work (11).

BAP and BBP were synthesized according to the method reported in our laboratory (30). The polymer BAP and BBP were dissolved in 100 l of methanol to a concentration of 20 mg/ml, and curcumin was also dissolved in 100 l of methanol to a concentration of 4 mg/ml. After mixing the two, the mixture was added dropwise to 2 ml of water or 5% glucose solution. After 3000-Da dialysis for 12 hours, the micelles C/ANP and C/BNP were obtained. C/ANP or C/BNP was incubated with siSNCA for 30 min at the appropriate N/P to obtain C/ANP/S or C/BNP/S. The incubation results were analyzed by gel electrophoresis. The final used N/P ratio was 5/1.

In general, exosomes were obtained from the primary bone marrowderived imDC. Experimental animals were 6- to 8-week-old mice (C57BL/6), specific pathogenfree (SPF) grade, and from Weitonglihua Company (China). The femur and tibia were obtained from the euthanized mice, and the bone marrow was washed with RPMI 1640 medium. The red blood cells were lysed, and the remaining cells were suspended with complete medium [95% RPMI 1640 medium, 5% exosome-free fetal bovine serum, recombinant mouse granulocyte-macrophage colony-stimulating factor (rmGM-CSF; 20 ng/ml), and IL-4 (20 ng/ml)]. The cells were cultured at 37C in an 5% CO2 incubator, and the complete medium was changed half per 2 days. The cell culture medium on the seventh day was collected. Next, the collected medium was configured at 400g at 4C for 5 min, the cells were removed, and the first supernatant was aspirated. Then, the supernatant was configured at 10,000g at 4C for 60 min, cell debris were removed, and the second supernatant was obtained. Next, the second supernatant was centrifuged in a 100-kDa ultrafiltration tube at 5000g at 4C for 30 min for three times, and 200 l of the concentrated medium supernatant solution was obtained. Therefore, cells and cell debris were removed by centrifugation, and concentrated medium was obtained from ultrafiltration. At last, the exosome fraction was collected by a qEV size exclusion column (Izon Science) to remove the protein and big vesicles. The obtained exosomes were measured for protein concentration by the BCA (bicinchoninic acid assay) kit, and 125 g of exosome was collected from one mouse. Exosomes were negatively stained with phosphotungstic acidnegative staining and observed under an electron microscope (JEM-1200EX).

RVG embedding exosome REXO was obtained by ultrasonic soaking for 5 min using an ultrasonic cleaner and cleaning three times by centrifugation through a 100-kDa ultrafiltration at 5000 revolutions per minute (rpm). REXO-C/ANP/S was prepared by ultrasonic soaking using a 40-kHz and 100-W ultrasonic cleaner for 15 min and cleaning three times by centrifugation through a 100-kDa ultrafiltration at 5000 rpm. Zeta potential and particle size of NPs were obtained by the Zetasizer Nano ZS90 (Malvern). The final mass ratio of C/ANP:siRNA:exosome was 4:1:0.5. NPs were observed under an electron microscope (JEM-1200EX).

Chitosan (10,000 to 20,000 molecular weight) was dissolved in 0.9 weight % NaCl HAc-NaAc buffer solution and was adjusted to pH 4.5. Two milliliters of chitosan solution was poured into a 60-ml oil phase (a mixture with liquid paraffintopetroleum ether ratio of 7:5), containing 1.8 g of Span 80, with 4000 rpm homogenization for 5 min, and then was washed with petroleum ether for three times. The natural drying chitosan microsphere initial emulsion was obtained. For chitosan microsphere adsorption, 60 l REXO-C/ANP/S was coincubated with 100 l of the chitosan microspheres obtained above, and then slides were prepared and observed under a confocal microscope (Zeiss LSM780).

Briefly, exosome and cells were lysed in reducing sample buffer [8% SDS, 0.25 M tris-HCl (pH 6.8), 40% glycerol, 5% 2-mercaptoethanol, and 0.04% bromophenol blue] and boiled for 10 min at 95C. Proteins were resolved by SDSpolyacrylamide gel electrophoresis, transferred to polyvinylidene fluoride membranes, blocked in 5% nonfat powdered milk in PBS-T (0.5% Tween 20), and probed with antibodies. They were incubated with antibodies (Abcam) and detected by an x-ray film after incubation with enhanced chemiluminescence reagent.

The NP-treated SH-SY5Y cells and SNCAmCherrySH-SY5Y cells were collected and analyzed by BD Calibur Flow cytometry (BD Co., USA). Cells were cultured in glass-bottom dishes (Cellvis), and the Cy5 mean fluorescence intensity and -synmCherry were calculated to measure the siRNA uptake using CLSM (Zeiss Co., Germany). Labeled exosome was obtained by incubating with 5 M of DiD for 30 min. The unincorporated dyes were removed using 300-kDa ultrafiltration centrifugation. DiI-labeled cell membrane was dissolved in the medium at a working concentration of 5 M. After coculture with the cells for 30 min, the medium was aspirated and washed repeatedly three times with the medium.

Experimental animals were 6- to 8-week-old mice (C57BL/6), SPF grade. MPTP was purchased from Sigma-Aldrich. The mice were intraperitoneally injected with MPTP (30 mg/kg) for seven consecutive days. In the treatment plan, mice were administered via tail vein injection with five numbers in each treatment group, and the cycle was once every other day for 10 times. After one treatment cycle, 100 l of blood was taken from the eyelids and collected. The total time of observation in the open field experiment was 30 min. Mouse IL-17A ELISA kit and mouse IL-10 ELISA kit were from LAIZEE, China. After the mice were euthanized, the brain was removed, paraffin sections were prepared, and the brain sections of the SN were stained with anti-syn, anti-TH, antiFox p3, and anti-CD4 antibody (Abcam). Presence of -syn aggregates in TH+ neurons and the presence of Fox p3 were analyzed by immune fluorescence staining. TH+ neurons were analyzed by immunohistochemistry staining. All procedures involving experimental animals were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of Peking University.

Acknowledgments: Funding: This work was financially supported by the Beijing Nova Program (Z201100006820140), the National High Technology Research and Development Program (2016YFA0200303), the National Natural Science Foundation of China (21905283, 31771095, and 21875254), and the Beijing Natural Science Foundation (2192057 and L172046). Author contributions: L.L., Y.L., and X.Z. designed the experiments. L.L., Y.L., H.P., R.L., W.J., and J.S. performed the experiments. L.L., Y.L., and X.Z. wrote the manuscript. Z.S. and G.M. edited the manuscript. All the authors analyzed the data and contributed to the paper. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

More:
Targeted exosome coating gene-chem nanocomplex as nanoscavenger for clearing -synuclein and immune activation of Parkinson's disease - Science...

A new research document is added in DBMR database of 350 pages, titled as Global Cancer Nanomedicine Market Size, Share, Growth, Trends, Industry By Type (Inorganic Nanoparticles, Organic Nanoparticles), Agent Type (Diagnostic Agents, Therapeutic Agents, Drug Delivery Agents), Mechanism (Targeting Tumor Cells, Nanocarrier Drug Complex, Drug Release Systems), Cancer Type (Breast Cancer, Pancreatic Cancer, Brain Cancer, Lung Cancer, Others), Imaging Technique (Positron Emission Tomography, Single Photon Emitted Tomography, Magnetic Resonance Imaging (MRI)), Phase (Research, Preclinical, Phase-I, Phase-I/II, Phase-II, Phase-III) Country and Forecast with detailed analysis, Competitive landscape, forecast and strategies. Latest analysis highlights high growth emerging players and leaders by market share that are currently attracting exceptional attention. The identification of hot and emerging players is completed by profiling 50+ Industry players; some of the profiled players are Alnylam Pharmaceuticals, Inc., Amgen Foundation, Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca, Cadila Pharmaceuticals, etc. The study conducted for Cancer Nanomedicine industry also analyses the market status, size, share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, and distributors with the help of SWOT analysis and Porters Five Forces Analysis.

Download Free Sample (350 Pages PDF, Full TOC, List of Tables & Figures, and Chart) Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-nanomedicine-market

Data Bridge Market Research analyses the Cancer Nanomedicine Market to grow at a CAGR of 12.50% in the forecast period. The growing usages of nanomedicine in drug delivery technology will further create various opportunities for the growth of the market.

The Cancer Nanomedicine Market report encompasses the general idea of the global Cancer Nanomedicine market including definition, classifications, and applications. Further, it includes the all-inclusive comprehension of several factors such as drivers, constraints, and major micro markets. The report is a wide-ranging source of widespread facts and figures for business strategists as it offers the historical &futuristic data such as demand & supply data, cost, revenue, profit, supply chain value, and so on. Furthermore, it entails the key market features, comprising production, revenue, price, capacity, gross margin, market share, consumption, gross, production rate, demand/supply, cost, capacity utilization rate, export/import, and CAGR (compound annual growth rate). In addition the report encompasses global Cancer Nanomedicine market segmentation on the basis of diverse facets like product/service type, application, technology, end-users, and major geographic regions North America, Europe, Asia-Pacific and Latin America. Apart from this, the researcher market analyst and experts present their outlook or insights of product sales, market share, and value along with the possible opportunities to grow or tap into in these regions.

Overview:

Surging volume of patients suffering from cancer, and other chronic disorders, increasing number of geriatric population across the globe, increasing development of nanotechnology-based drugs as well as therapies, adoption of advanced technologies are some of the factors which will likely to enhance the growth of the cancer nanomedicine market in the forecast period of 2020-2027. On the other hand, surging levels of investment on research and development activities along with introduction of advanced diagnostics procedure which will further bring immense opportunities for the growth of the cancer nanomedicine market in the above mentioned forecast period.

Low rate of adoption along with increasing side effects associated with the consumption of nanoparticles, stringent regulatory framework for approvals of drugs are acting as market restraints for the growth of the cancer nanomedicine market in the above mentioned forecast period.

According to this report Global Cancer Nanomedicine Market will rise from Covid-19 crisis at moderate growth rate during 2020 to 2027. Cancer Nanomedicine Market includes comprehensive information derived from depth study on Cancer Nanomedicine Industry historical and forecast market data. Global Cancer Nanomedicine Market Size To Expand moderately as the new developments in Cancer Nanomedicine and Impact of COVID19 over the forecast period 2020 to 2027.

To Understand How Covid-19 Impact Is Covered In This Report, Get Free Covid-19 Sample @ https://www.databridgemarketresearch.com/covid-19-impact/global-cancer-nanomedicine-market

Cancer Nanomedicine Market report provides depth analysis of the market impact and new opportunities created by the COVID19/CORONA Virus pandemic. Report covers Cancer Nanomedicine Market report is helpful for strategists, marketers and senior management, And Key Players in Cancer Nanomedicine Industry.

Key Segmentation:

By Type (Inorganic Nanoparticles, Organic Nanoparticles)

By Agent Type (Diagnostic Agents, Therapeutic Agents, Drug Delivery Agents)

By Mechanism (Targeting Tumor Cells, Nanocarrier Drug Complex, Drug Release Systems)

By Cancer Type (Breast Cancer, Pancreatic Cancer, Brain Cancer, Lung Cancer, Others)

By Imaging Technique (Positron Emission Tomography, Single Photon Emitted Tomography, Magnetic Resonance Imaging (MRI))

By Phase (Research, Preclinical, Phase-I, Phase-I/II, Phase-II, Phase-III)

Leading Players operating in the Cancer Nanomedicine Market are:

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart)@ https://www.databridgemarketresearch.com/covid-19-impact/global-cancer-nanomedicine-market

The Cancer Nanomedicine market report also entails the vigorous evaluation about the growth plot and all opportunities &risk related to of global Cancer Nanomedicine market during the forecast period. In addition, the report comprises the key events and most recent innovations in the industry together with the prospective trends technological progresses within the global Cancer Nanomedicine market that can impact its expansion graph. Entailing the pivotal data on the markets statistics and dynamics, the report will serve as a valued asset in term of decision-making and guidance for the businesses and companies already active within industry or looking forward to enter into it.

Global Cancer Nanomedicine Market Scope and Market Size

Cancer nanomedicine market is segmented on the basis of type, agent type, mechanism, cancer type, imaging technique, and phase. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on type, cancer nanomedicine market is segmented into inorganic nanoparticles, and organic nanoparticles. Inorganic nanoparticles have been further segmented into synthesis of gold nanoparticle. Organic nanoparticles have been further segmented into polymeric nanoparticle, and lipid organic nanoparticles.

On the basis of agent type, cancer nanomedicine market is segmented into diagnostic agents, therapeutic agents, and drug delivery agents. Diagnostic agents have been further segmented into cancer biomarkers, diagnostic device and nanoprobes, and quantum dots. Diagnostic device and nanoprobes have been further sub segmented into biosensors, and microarrays. Therapeutic agents have been further segmented into photodynamic therapy, and photo thermal therapy.

Based on mechanism, cancer nanomedicine market is segmented into targeting tumor cells, nanocarrier drug complex, and drug release systems. Targeting tumor cells have been further segmented into passive targeting, and active targeting. Nanocarrier drug complex have been further segmented into liposomes, dendrimers, micelles, and inorganic nanocarriers.

On the basis of cancer type, cancer nanomedicine market is segmented into breast cancer, pancreatic cancer, brain cancer, lung cancer, and others.

Based on imaging technique, cancer nanomedicine market is segmented into positron emission tomography, single photon emitted tomography, and magnetic resonance imaging (MRI).

Cancer nanomedicine market has also been segmented based on the phase into research, preclinical, phase-I, phase-I/II, phase-II, and phase-III.

Geographically, the following regions together with the listed national/local markets are fully investigated:

For More Information or Query or Customization before Buying, Visit @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cancer-nanomedicine-market

Reason to Buy

Access Full Report Directly @ https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-cancer-nanomedicine-market

Also, Research Report Examines:

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the global Cancer Nanomedicine Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product

Competition by Company: Here, the competition in the Worldwide Cancer Nanomedicine Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Cancer Nanomedicine Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Cancer Nanomedicine Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Cancer Nanomedicine Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Cancer Nanomedicine Market.

Market Forecast:Here, the report offers a complete forecast of the global Cancer Nanomedicine Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

Browse Complete Report Details @ https://www.databridgemarketresearch.com/reports/global-cancer-nanomedicine-market

Its vital you keep your market knowledge up to date. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization accordingly.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia or Oceania [Australia and New Zealand]

Customization Service of the Report:

Data Bridge Market Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team (Corporatesales@databridgemarketresearch.com), who will guarantee you to get a report that suits your necessities.

Our Others Reports:

Online Testing Software Market Trends, Size, Growth Insight, Industry Share, Emerging Technologies by ProProfs, QuizWorks, ExamSoft, EDBASE, Testment

Health Surveillance Systems Market Size, Trends, Future Growth, Latest Technology, Innovation With Competitive Analysis by Top Players-Avigilon, Schneider Electric, Cisco, Tyco Integrated Security, Nedap N.V., ADT

Hyperhidrosis Treatment Market Size, Industry Growth Analysis, Segmentation, Size, Share, Trend, Future Demand and Leading Players Updates by COVID-19 Impact Analysis 2027

Head Mirror Market Analysis with Top Trends, Size, Share, Leading Companies, Key Regions, Segments, Mergers and Foreseen By DBMR Till 2027

About Data Bridge Market Research, Private Ltd

Data Bridge Market ResearchPvtLtdis a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.

We provide a variety of services such as market verifiedindustry reports, technology trend analysis, Formative market research,strategic consulting, vendor analysis, production and demand analysis, consumer impact studies among many others.

Contact Us

US: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475

Email corporatesales@databridgemarketresearch.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Go here to read the rest:
Cancer Nanomedicine Market to Build Excessive Revenue at Healthy Growth rate at 12.50% up to 2027 - PharmiWeb.com

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN : FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the start of its roadshow in connection with its intention to issue and sell, subject to market and other conditions, 6,500,000 ordinary shares of the Company in an initial public offering of American Depositary Shares (ADSs), each representing one ordinary share, in the United States (the U.S. Offering) and a concurrent offering of ordinary shares in certain jurisdictions outside of the United States (the European Offering and, together with the U.S. Offering, the Global Offering). The Company intends to grant the underwriters for the Global Offering (the Underwriters) a 30-day option to purchase additional ADSs and/or ordinary shares in an aggregate amount of up to 15% of the total number of ADSs and ordinary shares proposed to be sold in the Global Offering.

All securities to be sold in the Global Offering will be offered by the Company. The Company has applied to list its ADSs on the Nasdaq Global Market under the ticker symbol "NBTX." The Companys ordinary shares are listed on the regulated market of Euronext in Paris under the symbol "NANO."

Jefferies LLC is acting as global coordinator and joint book-running manager for the Global Offering, and Evercore Group, L.L.C. and UBS Securities LLC are acting as joint book-running managers for the U.S. Offering. Jefferies International Limited and Gilbert Dupont are acting as managers for the European Offering.

The offering price per ADS in U.S. dollars and the corresponding offering price per ordinary share in euros, as well as the final number of ADSs and ordinary shares sold in the Global Offering, will be determined following a bookbuilding process.

The ADSs and/or ordinary shares will be issued through a capital increase without shareholders preferential subscription rights by way of a public offering excluding offerings referred to in Article L. 411-2 1 of the French Monetary and Financial Code (Code montaire et financier) and under the provisions of Article L.225-136 of the French Commercial Code (Code de commerce) and pursuant to the 2nd and 7th resolutions of the Company's extraordinary general shareholders' meeting held on November 30, 2020.

The European Offering will be open only to qualified investors as such term is defined in article 2(e) of the regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017.

The securities referred to in this press release will be offered only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the Global Offering may be obtained from Jefferies LLC, 520 Madison Avenue New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at Prospectus_Department@Jefferies.com; or from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at 888-474-0200, or by email at ecm.prospectus@evercore.com; or from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019, or by telephone at 888-827-7275, or by email at ol-prospectusrequest@ubs.com.

A registration statement on Form F-1 relating to the securities referred to herein has been filed with the U.S. Securities and Exchange Commission (SEC) but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The registration statement can be accessed by the public on the website of the SEC.

Application will be made to list the new ordinary shares to be issued pursuant to the Global Offering on the regulated market of Euronext in Paris pursuant to a listing prospectus subject to an approval from the French Autorit des marchs financiers (AMF) and comprising the 2019 Universal Registration Document (Document d'Enregistrement Universel) of the Company approved by the AMF on May 12, 2020 under number R. 20-010, as amended by its amendment filed with the AMF on November 20, 2020 under number D.20-0339-A01 and a Securities Note (Note dopration), including a summary of the prospectus. Copies of the 2019 Universal Registration Document and its amendment are available free of charge at the Companys head office located at 60, rue de Wattignies, 75012 Paris, France, on the Companys website (www.nanobiotix.com) and on the website of the AMF (www.amf-france.org).

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About NANOBIOTIX

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). Its headquarters are in Paris, France. Nanobiotix has a subsidiary, Curadigm, located in France and the United States, as well as a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.

Disclaimer

This press release contains certain forward-looking statements concerning the Global Offering as well as Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix registered with the AMF under number R.20-010 on May 12, 2020 and in its amendment filed with the AMF under number D.20-0339-A01 on November 20, 20 (copies of which are available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

See the original post here:
Nanobiotix Announces the Start of the Roadshow for Its Proposed Global Offering and Proposed Nasdaq Listing - Business Wire

Tel Aviv University researchers use tiny molecular scissors to target aggressive metastatic cancer cells

Israeli scientists have developed a cutting-edge nanotechnology system that can destroy cancerous cells in mice.

The Tel Aviv University team of researchers pioneered a treatment method that is so precise, it is almost as if tiny molecular scissors were being used to kill the cancer.

We developed a delivery system for these molecular scissors that can specifically reach tumor cells while leaving normal cells intact, Dr. Daniel Rosenblum, a postdoctoral fellow from the Laboratory of Precision NanoMedicine at the Shmunis School of Biomedicine and Cancer Research at Tel Aviv University, told The Media Line.

By cutting their DNA in specific genes that are responsible for cell division or cell survival, we basically neutralize them and they die from the treatment, he said. The system we developed is based on the Cas9 CRISPR protein in a [messenger] RNA format.

The process, known as CRISPR genome editing, allows researchers to alter DNA sequences. Specifically, scientists at the university created what is known as CRISPR-LNPs, a lipid nanoparticle delivery system that carries a genetic messenger (known as messenger RNA), along with a navigation system that can recognize cancerous cells.

The findings of the peer-reviewed research were published last month in the Science Advances journal.

This is the first study in the world to prove that the CRISPR genome editing system can be used to treat cancer in a living animal effectively,said Prof. Dan Peer, vice president for Research and Development at Tel Aviv University and head of TAUs Laboratory of Precision NanoMedicine.

The idea there is to take the cells from the patients, edit them in a plate outside the body and then inject them back into the patient, he told The Media Line. We believe that this could be expanded to much more than just the two models that we have tried.

So far, researchers at Tel Aviv University have tested the technology on mice and have observed no adverse reactions. This stands in contrast to chemotherapy, which kills both cancerous and healthy cells.

The CRISPR-LNPs were tested on glioblastoma tumors, an extremely aggressive type of brain cancer that has a five-year survival rate of only 3%. In addition, the researchers tested the system on metastatic ovarian cancer, a major cause of death among women and the most lethal cancer in the female reproductive system.

Wake up to the Trusted Mideast News source Mideast Daily News Email

For the glioblastoma tumors, the treatment was found to double the average life expectancy of mice and improve their overall survival rate by about 30%. For ovarian cancer, the overall survival rate rose by a whopping 80%.

When we started we thought this was a science-fiction approach but basically it works, at least in the animal models that we have tried

We envision that we can simply inject [the treatment] into the body and because of the GPS they can find their way to the tumor, Anna Gutkin, a doctoral student in the laboratory, told The Media Line. We encountered several hurdles in the development of this technology but its exciting to work on this. It really opens new avenues for us to develop novel therapies.

Aside from its potentially revolutionary impact on future cancer treatments, the technology also opens the door for treating rare genetic diseases and viral diseases such as AIDS, according to the researchers. A similar technology based on messenger RNA currently is being used by Pfizer (BioNTech) and Moderna for their COVID-19 vaccines.

Our system is a bit more sophisticated both from the materials they are created from [and] we also gave it a GPS system, which is pretty unique, Rosenblum noted.

In the future, Peer and his team hope to test the groundbreaking technology on larger animal models. Human trials are expected to begin in about two years.

Because of the coronavirus crisis we have witnessed how fast new approaches could be translated into the clinic, Peer said.

When we started we thought this was a science-fiction approach but basically it works, at least in the animal models that we have tried, he concluded.

The rest is here:
Israeli Scientists Kill Cancer With Revolutionary DNA-Altering Treatment (with VIDEO) - The Media Line